A School-Based Human Papillomavirus Vaccination Program in Barretos, Brazil: Final Results of a Demonstrative Study

Show simple item record

dc.contributor Sistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP
dc.contributor.author FREGNANI, Jose Humberto Tavares Guerreiro
CARVALHO, Andre Lopes
ELUF-NETO, Jose FMUSP-HC
RIBEIRO, Karina de Cassia Braga
KUIL, Larissa de Melo
SILVA, Tauana Arcadepani da
RODRIGUES, Silvia Lapola
MAUAD, Edmundo Carvalho
LONGATTO-FILHO, Adhemar FMUSP-HC
VILLA, Luisa Lina
dc.date.issued 2013
dc.identifier.citation PLOS ONE, v.8, n.4, article ID e62647, 9p, 2013
dc.identifier.issn 1932-6203
dc.identifier.uri http://observatorio.fm.usp.br/handle/OPI/2101
dc.description.abstract Introduction: The implementation of a public HPV vaccination program in several developing countries, especially in Latin America, is a great challenge for health care specialists. Aim: To evaluate the uptake and the three-dose completion rates of a school-based HPV vaccination program in Barretos (Brazil). Methods: The study included girls who were enrolled in public and private schools and who regularly attended the sixth and seventh grades of elementary school (mean age: 11.9 years). A meeting with the parents or guardians occurred approximately one week before the vaccination in order to explain the project and clarify the doubts. The quadrivalent vaccine was administered using the same schedule as in the product package (0-2-6 months). The school visits for regular vaccination occurred on previously scheduled dates. The vaccine was also made available at Barretos Cancer Hospital for the girls who could not be vaccinated on the day when the team visited the school. Results: Among the potential candidates for vaccination (n = 1,574), the parents or guardians of 1,513 girls (96.1%) responded to the invitation to participate in the study. A total of 1,389 parents or guardians agreed to participate in the program (acceptance rate = 91.8%). The main reason for refusing to participate in the vaccination program was fear of adverse events. The vaccine uptake rates for the first, second, and third doses were 87.5%, 86.3% and 85.0%, respectively. The three-dose completion rate was 97.2%. Conclusions: This demonstrative study achieved high rates of vaccination uptake and completion of three vaccine doses in children 10-16 years old from Brazil. The feasibility and success of an HPV vaccination program for adolescents in a developing country may depend on the integration between the public health and schooling systems.
dc.description.sponsorship · CNPq [573799/2008-3]
· FAPESP [2008/57889-1]
· MISP (Merck Investigator Studies Program)
· Merck Co., Inc.
dc.language.iso eng
dc.publisher PUBLIC LIBRARY SCIENCE
dc.relation.ispartof Plos One
dc.rights openAccess
dc.subject.other hpv vaccination; quadrivalent vaccine; delivery strategies; particle vaccine; income countries; united-states; coverage; australia; efficacy; trial
dc.title A School-Based Human Papillomavirus Vaccination Program in Barretos, Brazil: Final Results of a Demonstrative Study
dc.type article
dc.rights.holder Copyright PUBLIC LIBRARY SCIENCE
dc.description.group LIM/14
dc.description.group LIM/38
dc.identifier.doi 10.1371/journal.pone.0062647
dc.identifier.pmid 23638130
dc.type.category original article
dc.type.version publishedVersion
hcfmusp.author ELUF-NETO, Jose:FM:MPR
hcfmusp.author LONGATTO-FILHO, Adhemar:HC:LIM/14
hcfmusp.author.external · FREGNANI, Jose Humberto Tavares Guerreiro:Barretos Canc Hosp IEP HCB, Res & Teaching Inst, Barretos, Brazil; Santa Casa Sao Paulo Med Sch FCMSCSP, Natl Inst Sci & Technol Dis Associated Papillomav, Sao Paulo, Brazil
· CARVALHO, Andre Lopes:Barretos Canc Hosp IEP HCB, Res & Teaching Inst, Barretos, Brazil
· RIBEIRO, Karina de Cassia Braga:Santa Casa Sao Paulo Med Sch FCMSCSP, Natl Inst Sci & Technol Dis Associated Papillomav, Sao Paulo, Brazil; Santa Casa Sao Paulo Med Sch FCMSCSP, Dept Social Med, Sao Paulo, Brazil
· KUIL, Larissa de Melo:Barretos Canc Hosp IEP HCB, Res & Teaching Inst, Barretos, Brazil
· SILVA, Tauana Arcadepani da:Barretos Canc Hosp IEP HCB, Res & Teaching Inst, Barretos, Brazil
· RODRIGUES, Silvia Lapola:Barretos Canc Hosp IEP HCB, Res & Teaching Inst, Barretos, Brazil
· MAUAD, Edmundo Carvalho:Barretos Canc Hosp IEP HCB, Res & Teaching Inst, Barretos, Brazil
· VILLA, Luisa Lina:Santa Casa Sao Paulo Med Sch FCMSCSP, Natl Inst Sci & Technol Dis Associated Papillomav, Sao Paulo, Brazil
hcfmusp.origem.id WOS:000318340400119
hcfmusp.origem.id 2-s2.0-84876533181
hcfmusp.publisher.city SAN FRANCISCO
hcfmusp.publisher.country USA
hcfmusp.relation.reference · Arrossi S, 2012, VACCINE, V30, P2467, DOI 10.1016/j.vaccine.2012.01.032
· Brasil, 2010, CENS 2010
· Brazil, 2011, SI PNI SIST INF PROG
· Brotherton JML, 2011, LANCET, V377, P2085, DOI 10.1016/S0140-6736(11)60551-5
· Burchell AN, 2006, VACCINE, V24, P52, DOI 10.1016/j.vaccine.2006.05.031
· Dorell Christina, 2012, Morbidity and Mortality Weekly Report, V61, P671
· Chadenier GMC, 2011, VACCINE, V29, P4405, DOI 10.1016/j.vaccine.2011.04.007
· Fagot JP, 2011, VACCINE, V29, P3610, DOI 10.1016/j.vaccine.2011.02.064
· Fairley CK, 2009, SEX TRANSM INFECT, V85, P499, DOI 10.1136/sti.2009.037788
· Ferlay J, 2011, IARC CANCERBASE
· Ferlay J, 2010, INT J CANCER, V127, P2893, DOI 10.1002/ijc.25516
· Garland SM, 2011, PREV MED, V53, pS29, DOI 10.1016/j.ypmed.2011.08.015
· Garland SM, 2007, NEW ENGL J MED, V356, P1928, DOI 10.1056/NEJMoa061760
· Goldie SJ, 2007, VACCINE, V25, P6257, DOI 10.1016/j.vaccine.2007.05.058
· Immunise Australia Program. Human Papillomavirus (HPV), 2011, HUM PAP HPV INF NAT
· Ladner J, 2012, BMC PUBLIC HEALTH, V12, DOI 10.1186/1471-2458-12-370
· LaMontagne DS, 2011, B WORLD HEALTH ORGAN, V89, P821, DOI [10.2471/BLT.11.089862, 10.2471/BLT.11.08986, 10.1590/S0042-96862011001100012]
· Lehtinen M, 2012, LANCET ONCOL, V13, P89, DOI 10.1016/S1470-2045(11)70286-8
· Limia A, 2011, EURO SURVEILL, V16
· Paavonen J, 2009, Lancet, V374, P301, DOI 10.1016/S0140-6736(09)61248-4
· Parkin DM, 2006, VACCINE, V24, P11, DOI 10.1016/j.vaccine.2006.05.111
· Rondy M, 2010, VACCINE, V28, P2070, DOI 10.1016/j.vaccine.2009.12.042
· Rouzier R, 2010, J ADOLESCENT HEALTH, V47, P237, DOI 10.1016/j.jadohealth.2010.04.006
· Saslow D, 2007, CA-CANCER J CLIN, V57, P7
· Simoens C, 2009, EURO SURVEILL, V14
· Singh Y, 2010, ASIAN PAC J CANCER P, V11, P615
· Stokley S, 2011, PEDIATRICS, V128, P1078, DOI 10.1542/peds.2011-1048
· Vanni T, 2012, VACCINE, V30, P4866, DOI 10.1016/j.vaccine.2012.04.087
· Villa LL, 2006, BRIT J CANCER, V95, P1459, DOI 10.1038/sj.bjc.6603469
· Villa LL, 2011, CANCER LETT, V305, P106, DOI 10.1016/j.canlet.2010.12.002
· Villa LL, 2005, LANCET ONCOL, V6, P271, DOI 10.1016/S1470-2045(05)70101-7
· Watson M, 2009, AUST NZ J PUBL HEAL, V33, P365, DOI 10.1111/j.1753-6405.2009.00409.x
· Watson-Jones D, 2012, J INFECT DIS, V206, P678, DOI 10.1093/infdis/jis407
· WHO, 2012, IMM SUMM STAT REF CO, P198
· Widgren K, 2011, VACCINE, V29, P9663, DOI 10.1016/j.vaccine.2011.10.021
· World Health Organisation, 2009, WEEKLY EPIDEMIOLOGIC, V15, P118
· [Anonymous], 2011, MMWR MORB MORTAL WKL, V60, P1382
· [Anonymous], 2007, N ENGL J MED, V356, P1915
· [Anonymous], 2010, NAT STAT LOC AR VACC, P1018
· WHO, 2011, IN VACC RES IVR VIR
dc.description.index MEDLINE
hcfmusp.citation.scopus 29
hcfmusp.affiliation.country Brasil
hcfmusp.scopus.lastupdate 2021-07-14


Files in this item

This item appears in the following Collection(s)

Show simple item record

Search DSpace



Browse

My Account

Statistics